Copyright © 2001 by the European Society of Cardiology.
Editorials
Diagnosing myocardial iron overload
Royal Free Hospital, London, U.K.
References
- Hussain MAM, Flynn DM, Green N, Hussein S, Hoffbrand AV. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet. 1976;2:1278–1280[Medline]
- Propper RL, Cooper B, Rufo RR. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977;297:418–423[Abstract]
- Zurlo MF, DeStefano P, Borgna Pignatti C. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27–30[Web of Science][Medline]
- Gabutti V, Piga A. Results of long-term iron chelating therapy. Acta Haematologica. 1996;95:26–36[Web of Science][Medline]
- Wolfe L, Olivieri N, Sallam D. Prevention of disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312:166–1603
- Aldouri MA, Hoffbrand AV, Flynn DM. High incidence of cardiomyopathy in beta thalassaemia patients receiving transfusion and iron chelation: reversal by intensified chelation. Acta Haemato. 1990;84:113–117
- Link G, Saada A, Pinson A, Konijn AM, Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med. 1998;131:466–474[CrossRef][Medline]
- Al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum iron-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haemat. 1992;82:431–436[Web of Science][Medline]
- Olivieri NF, Nathan DG, MacMillan JH. Survival in medically treated patients with homozygous ß thalassemia. N Engl J Med. 1994;331:574–578
[Abstract/Free Full Text] - Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–761
[Free Full Text] - Anderson L, Holden S, Davis B. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179
[Abstract/Free Full Text] - Marcus RE, Davies SC, Bartock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet. 1984;1:392[Medline]
- Porter JB. A risk benefit assessment of iron-chelation therapy. Drugs Safety. 1997;17:407–421
- Barman Balfour KA, Foster RH. Deferiprone: A review of its clinical potential in iron overload in ß-thalassaemia major and other transfusion-dependent diseases. Drugs. 1999;3:553–578
- Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haemat. 1998;103:361–364[CrossRef][Medline]
- Breuer W, Erners MJJ, Pootrakul P, Abramov A, Hershko C, Cabantenik ZI. Desferrioxamine-chelatable iron a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792–798
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Bluemke and R. P. Liddell Can MR Imaging Provide a Noninvasive "Biopsy" of the Heart to Measure Iron Levels? Radiology, March 1, 2005; 234(3): 647 - 648. [Full Text] [PDF]
|
|
|
|
 |
|
 M Vogel, L.J Anderson, S Holden, J.E Deanfield, D.J Pennell, and J.M Walker Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload Eur. Heart J., January 1, 2003; 24(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||